Dr Anam Naz, Dr Shumaila Nasreen, Dr Muhammad Usman Afzal
Introduction: Coronary artery disease is the leading cause of death in the US, Europe and developed countries. Objectives: To evaluate the clinical benefit of using trimetazidine in acute MI with thrombolytic therapy. 100 patients with acute MI were enrolled in the study. Patients and Methods: This study was conducted in the Medical department of Holy Family Hospital and Benazir Bhutto Hospital Rawalpindi for six months duration from 1st November 2019 to 30th April 2020 on 100 patients meeting criteria for acute MI during this study. Results: One hundred patients were qualified to group I and group II (50 patients each). In group I, 50 patients were treated with thrombolytic therapy, i.e. with streptokinase alone. In group II, 50 patients were treated with streptokinase together with trimadizidine. These patients were followed up to the sixth month and complications such as arrhythmia, congestive heart failure, bleeding, re-infarction, angina and death were compared in both groups. Key words: Vestral MR, Acute MI, Trimetazidine.